Published March 31, 2025 | Version v1
Journal article Open

FORMULATION AND EVALUATION OF TRANSDERMAL PATCH OF SILDENAFIL CITRATE

Authors/Creators

  • 1. SSM College of Pharamacy, Jambai, Erode. The Tamilnadu Dr. MGR Medical University Chennai.

Abstract

The objective of this study was to formulate and evaluate a transdermal patch of sildenafil citrate to enhance its bioavailability, reduce first-pass metabolism, and provide sustained release. Sildenafil citrate, a phosphodiesterase type 5 inhibitor, is commonly used in the treatment of erectile dysfunction but faces limitations related to its oral bioavailability and short half-life. Transdermal drug delivery offers an alternative route of administration that can bypass the gastrointestinal tract and liver metabolism, thereby improving therapeutic outcomes. The sildenafil citrate patches were prepared using different polymers hydroxypropyl methylcellulose,and plasticizers polyethylene glycol to optimize the release characteristics. The patches were evaluated for various physicochemical properties, including thickness, weight uniformity and drug content. In vitro drug release studies were conducted using a Franz diffusion cell to determine the release profile of sildenafil citrate. The results showed that the patches exhibited a controlled release over 24 hours, with a significant increase in drug permeation across the skin compared to conventional oral formulations. The stability studies indicated that the patches were stable under accelerated conditions, with no significant degradation of sildenafil citrate. The formulation demonstrated potential for effective transdermal delivery, providing a novel approach for sustained-release sildenafil therapy, which could improve patient compliance and therapeutic efficacy.

Files

13 WJPSR 940.pdf

Files (1.9 MB)

Name Size
md5:849bc84ba4c8d5823b782b4f80a09805
1.9 MB Preview Download

Additional details

References

  • 1. Debjitbbowmik, Chiranjib, Margetchandira, jayakar B. Sampath.K.P. Recent advances in transdermal drug delivery system. International journal of pharm tech research, Year: 2010; 2: 68-77.
  • 2. Divyeshpatel.neravpatel, mehalparmar, Navpreetkaur, transdermal drug delivery system Review, Year: 2011; 1: 61-80.
  • 3. Langer R. Transdermal drug delivery: past progress, current status, and future prospects. Adv Drug Dev Rev, 2004; 56: 557-558.
  • 4. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol, 2008; 26: 1261-1268.
  • 5. Eseldinkeleb, Rakashkumar Sharma, Esmaeil B mosa, Abdalkadar Z aljahwi Review Transdermal drug delivery system-Design and Evaluation international journal of advances pharmaceutical sciences. Your 2011 puge 201-211.
  • 6. Shravani.P, VinothK.R, TejaB.B, DavidBanji. Designing and Charecterisation of Reservoir type transdermal Formulation of Fulvestrant, Year: 2010; 5(3): 59-63.
  • 7. O'Rourke, M. F., M.D., D.Sc., et al., Arterial vasodilator effects on central aortic pressure and systolic blood pressure. Hypertension, 2006; 47(4): 850-854.
  • 8. Geetha Aggarwal, Aravind Goel, Sanjudhawanarvind. Carriers/ vesicle based approaches for penetration enhancement in transdermal drug delivery system. Pharmainfo.net. year: 2010.
  • 9. Ashok kumar J. Nikhilapullakandam, Lakshmanaprahu S. Gopal. V. Transdermal drug delivery system an over view. International journal of pharmaceutical sciences review and research, Year: 2010; 1(2): 45-54.
  • 10. Shravani.P, VinothK.R, TejaB.B, DavidBanji. Designing and Charecterisation of Reservoir type transdermal Formulation of Fulvestrant. Year: 2010; 5(3): 59-63.
  • 11. GEINOZ S, GUY RH, TESTA B., Quantitative showture permeation relationships to proflict skin permention, 2004.
  • 12. CEVC G., VIER IU., Nanotechnology and the transdermal route, 2010.
  • 13. ESCOBAR-CHAVEZ 33.etal., Nanocarriers Re transdermal drug delivery research and reports in transdermal drug delivery, 2012; 1: 3-17.
  • 14. McCullough AR. Four-year review of sildenafil citrate. Rev Urol, 2002; 4 Suppl 3(Suppl 3): S26-38. [PMC free article] [PubMed]
  • 15. Albersen M, Shindel AW, Mwamukonda KB, Lue TF. The future is today: emerging drugs for the treatment of erectile dysfunction. Expert OpinEmerg Drugs, 2010 Sep; 15(3): 467-80. [PMC free article] [PubMed]
  • 16. Fallah F. Recent strategies in treatment of pulmonary arterial hypertension, a review. Glob J Health Sci, 2015 Jan 26; 7(4): 307-22. [PMC free article] [PubMed]
  • 17. Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol, 2000 Aug; 50(2): 99-107. [PMC free article] [PubMed]
  • 18. Coons JC, Pogue K, Kolodziej AR, Hirsch GA, George MP. Pulmonary Arterial Hypertension: a Pharmacotherapeutic Update. CurrCardiol Rep, 2019 Nov 22; 21(11): 141. [PubMed]
  • 19. Han MK, Bach DS, Hagan PG, Yow E, Flaherty KR, Toews GB, Anstrom KJ, Martinez FJ., IPFnet Investigators. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest, 2013 Jun; 143(6): 1699-1708. [PMC free article] [PubMed]
  • 20. Huang S, DeSantis ER. Treatment of pulmonary arterial hypertension in pregnancy. Am J Health Syst Pharm, 2007 Sep 15; 64(18): 1922-6. [PubMed]
  • 21. https://www.mayoclinic.org/diseases-conditions/erectile-dysfunction/symptoms-causes/syc-20355776?p=1
  • 22. Muneer A, Kalsi J, Nazareth I, Arya M. Erectile dysfunction. BMJ, 2014 Jan 27; 348: g129. [PubMed]
  • 23. Shamloul R, Ghanem H. Erectile dysfunction. Lancet, 2013 Jan 12; 381(9861): 153-65. [PubMed]
  • 24. Orimoloye OA, Feldman DI, Blaha MJ. Erectile dysfunction links to cardiovascular disease-defining the clinical value. Trends Cardiovasc Med, 2019 Nov; 29(8): 458-465. [PubMed]
  • 25. Miner M, Nehra A, Jackson G, Bhasin S, Billups K, Burnett AL, Buvat J, Carson C, Cunningham G, Ganz P, Goldstein I, Guay A, Hackett G, Kloner RA, Kostis JB, LaFlamme KE, Montorsi P, Ramsey M, Rosen R, Sadovsky R, Seftel A, Shabsigh R, Vlachopoulos C, Wu F. All men with vasculogenic erectile dysfunction require a cardiovascular workup. Am J Med, 2014 Mar; 127(3): 174-82. [PubMed]
  • 26. Miner M, Parish SJ, Billups KL, Paulos M, Sigman M, Blaha MJ. Erectile Dysfunction and Subclinical Cardiovascular Disease. Sex Med Rev, 2019 Jul; 7(3): 455-463. [PubMed]
  • 27. Corona G, Rastrelli G, Isidori AM, Pivonello R, Bettocchi C, Reisman Y, Sforza A, Maggi M. Erectile dysfunction and cardiovascular risk: a review of current findings. Expert Rev Cardiovasc Ther, 2020 Mar; 18(3): 155-164. [PubMed]
  • 28. Randrup E, Baum N, Feibus A. Erectile dysfunction and cardiovascular disease. Postgrad Med, 2015 Mar; 127(2): 166-72. [PubMed]
  • 29. Matsui H, Sopko NA, Hannan JL, Bivalacqua TJ. Pathophysiology of erectile dysfunction. Curr Drug Targets, 2015; 16(5): 411-9. [PubMed]
  • 30. Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am, 2005 Nov; 32(4): 379-95, v. [PMC free article] [PubMed]
  • 31. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. BiochemBiophys Res Commun, 1990 Jul 31; 170(2): 843-50. [PubMed]
  • 32. Giuliano F. Neurophysiology of erection and ejaculation. J Sex Med, 2011 Oct; 8 Suppl 4: 310-5. [PubMed]
  • 33. Badr-Eldin, S. M., & Ahmed, O. A. et al., Formulation and evaluation of sildenafil citrate (SLD) nano-transfersomal transdermal films with enhanced and controlled permeation for improved bioavailability. Journal of Drug Delivery Science and Technology, 2016; 36: 124-133.
  • 34. Abdelalim, L.R., et al., Sildenafil citrate-loaded oleosomes for topical management of palmar-plantar erythrodysesthesia (PPE). Journal of Drug Delivery Science and Technology, 2020; 60: 101979.
  • 35. Diany Elim, et al., Development of hydrogel-forming microneedles for transdermal delivery of sildenafil citrate in erectile dysfunction therapy. European Journal of Pharmaceutical Sciences, 2023; 186: 105467.
  • 36. Andi Maqhfirah Nurul Fitri, et al., Development of hydrogel-forming microneedles and tablet reservoir system for transdermal delivery of sildenafil citrate in pulmonary hypertension therapy. European Journal of Pharmaceutical Sciences, 2023; 204: 106312.
  • 37. Gamea, R. M. R., et al., Clinical effect of sildenafil citrate tablets and nitric oxide patch for the treatment of first trimester pregnant women with a history of unexplained recurrent spontaneous abortion. Journal of Obstetrics and Gynecology Research, 2018; 44(9): 1699-1705.
  • 38. O'Rourke, M. F., M.D., D.Sc., et al., Arterial vasodilator effects on central aortic pressure and systolic blood pressure. Hypertension, 2006; 47(4): 850-854.
  • 39. Sulistiawati, S., et al., Development of a novel transdermal delivery system for sildenafil citrate using hydrogel-forming microneedles and inclusion complex tablet reservoir to improve solubility and bioavailability. International Journal of Pharmaceutics, 2024; 587: 119688.
  • 40. Hamzehnejadi, M. S., et al., Pharmacotherapy of erectile dysfunction: Challenges and future prospects for drug formulations with reduced side effects and interactions. Journal of Clinical Pharmacy and Therapeutics, 2022; 47(2): 161-170.
  • 41. Patel, H., et al., Premature Ejaculation and the Role of Sildenafil Citrate in Its Treatment: Advances in Transdermal Drug Delivery Systems. Journal of Sexual Medicine, 2012; 9(3): 574-580.
  • 42. Refai, H., Hassan, D., & Abdelmonem, R. et al., Development of Sildenafil-Loaded Liposomes Coated with Bioadhesive Polymers for Enhanced Vaginal Retention and Improved Drug Permeation. International Journal of Pharmaceutics, 2017; 529(1-2): 231-240.
  • 43. Mewada, V., et al., Development and evaluation of an immediate release, taste masked orodispersible film (ODF) of sildenafil citrate for the management of pulmonary arterial hypertension (PAH). Journal of Pharmaceutical Sciences, 2024.
  • 44. Hosny, K. M., Aljaeid, B. M., et al., Preparation and characterization of sildenafil citrate-loaded solid lipid nanoparticles (SLNs) for improved oral bioavailability. International Journal of Nanomedicine, 2014; 9: 2357-2365. https://doi.org/10.2147/IJN.S63427
  • 45. Baek, O. S., et al., Development of a transdermal gel loaded with tadalafil for enhanced solubility and bioavailability. International Journal of Pharmaceutics, 2015; 495(1-2): 424-433.
  • 46. Ishikura, F., et al., Effects of sildenafil citrate on systemic blood pressure and coronary blood flow: A study on its interaction with nitroglycerin. Journal of Cardiovascular Pharmacology and Therapeutics, 2020; 25(5): 437-444. https://doi.org/10.1177/1074248420952863
  • 47. Kader, G. A., et al., Smoking aggravates skin necrosis as a complication of random-pattern flap ischemia. Sildenafil and nitroglycerin as vasodilators improve skin flap survival. Journal of Surgical Research, 2020; 253: 225-234. https://doi.org/10.1016/j.jss.2020.03.038
  • 48. Ebert, T., et al., Testosterone therapy for hypogonadism: Benefits and challenges in the treatment of late-onset hypogonadism. Journal of Clinical Endocrinology & Metabolism, 2005; 90(6): 3451-3459. https://doi.org/10.1210/jc.2005-0239
  • 49. El-Bheirey, A. M., et al., Intrauterine growth restriction (IUGR): Diagnosis, treatment, and challenges in obstetrics. Journal of Obstetrics and Gynaecology Research, 2018; 44(7): 1234-1242. https://doi.org/10.1111/jog.13709
  • 50. Sanford, M., et al., Rotigotine transdermal patch for the treatment of Parkinson's disease: A review of its efficacy and safety. Drugs, 2012; 72(13): 1795-1807.
  • 51. Nangare, S., et al., Advances in the pharmaceutical formulations for the treatment of erectile dysfunction: A review on novel drug delivery systems. Journal of Pharmacy & Bioallied Sciences, 2020; 12(1): 1-13. https://doi.org/10.4103/jpbs.JPBS_107_19
  • 52. Ferreira, A., et al., Pharmacological advances in erectile dysfunction (ED) treatment have aroused growing interest among health professionals towards sexual dysfunction, generating an increasing demand for dosage forms and drug delivery systems, including tadalafil. This study aimed to develop a device to generate patches that would enable drug dosage individualization and transdermal administration. International Journal of Pharmaceutics, 2017; 525(1-2): 143-153. https://doi.org/10.1016/j.ijpharm.2017.04.024
  • 53. Abdeldayem, T. M., et al., Sildenafil citrate in the management of intrauterine growth restriction: A potential treatment for IUGR and premature labor. Journal of Obstetrics and Gynaecology Research, 2016; 42(4): 522-527. https://doi.org/10.1111/jog.13017.
  • 54. Pervaiz, F., et al., Preparation and characterization of paroxetine-loaded solid lipid nanoparticles (SLNs) for sustained-release transdermal patches: Enhancement of drug absorption and bioavailability. International Journal of Pharmaceutics, 2023; 642: 122000. https://doi.org/10.1016/j.ijpharm.2023.122000
  • 55. Sultana, N., et al., Development of microneedle transdermal patches loaded with optimized nanotransfersomes of risedronate sodium and ursolic acid for the treatment of osteoporosis. International Journal of Pharmaceutics, 2023; 625: 121948. https://doi.org/10.1016/j.ijpharm.2023.121948
  • 56. Meadows, K. L., et al., Topical sildenafil cream for the treatment of palmar-plantar erythrodysesthesia: A randomized, double-blind, placebo-controlled pilot study. Supportive Care in Cancer, 2015; 23(4): 1181-1188. https://doi.org/10.1007/s00520-014-2494-3.
  • 57. Yadav, K. S., et al., Microemulsions as a drug delivery system for hydrophilic drugs: A review on their use for oral, nasal, transdermal, and ocular administration. Journal of Drug Delivery Science and Technology, 2023; 84: 104446.
  • 58. https://medlineplus.gov/druginfo/meds/a692025.html
  • 59. https://www.drugs.com/sildenafil.html
  • 60. https://www.mayoclinic.org/drugs-supplements/sildenafil-oral-route/description/drg-20069476
  • 61. https://pubchem.ncbi.nlm.nih.gov/.
  • 62. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
  • 63. Patel, P. A., & Patel, M. A., Ethyl Cellulose: A Review on Pharmaceutical Applications and Techniques. International Journal of Pharmaceutical Sciences and Research, 2011; 2(8): 1743-1750.
  • 64. Ghaffari, M. & Rezaei, M., "Polyethylene Glycol (PEG) in Drug Delivery: Applications and Biological Implications." Journal of Biomaterials Science, Polymer Edition, 2019; 30(4): 375394. DOI:[10.1080/09205063.2019.1592827] (https://doi.org/10.1080/09205063.2019.1592827)
  • 65. Nabors, L., "Polyethylene Glycol (PEG): A Versatile Pharmaceutical Excipient." International Journal of Pharmaceutical Compounding, 2001; 5(5): 326-333.
  • 66. Siegenthaler, W. & Liversidge, G., "Polyethylene Glycol (PEG): Properties, Applications, and Safety." Pharmaceutical Technology, 1999; 23(4): 74-80. [Link](https://www.pharmtech.com/view/polyethylene-glycol-peg-properties-applications-and-safety)
  • 67. https://pubchem.ncbi.nlm.nih.gov/compound/Oleic-Acid
  • 68. https://www.sciencedirect.com/topics/chemistry/oleic-acid
  • 69. Mr. Hiren Patel*, Ms. Mital S. Panchal, Mr. Suresh Shah, Dr. K.R.Vadalia Shree H. N. Shukla, Formulation and Evaluation of Transdermal Gel of Sildenafil Citrate, 2012; 1(3): 103-118.